Alicioglu, Banu; Saynak, Mert
Metástases nas leptomeninges da espinal medula num doente com carcinoma de células escamosas do pulmão
Revista Portuguesa de Pneumologia, vol. XIV, núm. 6, noviembre-diciembre, 2008, pp. 875-879
Sociedade Portuguesa de Pneumologia
Lisboa, Portugal

Disponível em: http://www.redalyc.org/articulo.oa?id=169718435011
Caso Clínico

Metástases nas leptomeninges da espinal medula num doente com carcinoma de células escamosas do pulmão

Spinal leptomeningeal metastasis in a patient with squamous cell lung cancer

As metástases nas leptomeninges da espinal medula ocorrem raramente nos tumores sólidos e o prognóstico é bastante reservado. Os adenocarcinomas e os carcinomas de pequenas células são os grupos histológicos mais envolvidos no que se refere aos tumores pulmonares. Um homem de 58 anos com história de carcinoma de células escamosas do pulmão com inversão mediastínica e metástases cerebrais apresenta lombalgias e fraqueza em ambos os membros inferiores. A RMN da coluna vertebral revelou espessamento na espinal medula e múltiplos nódulos do grupo das fibras da cauda equina. Tanto quanto sabemos, trata-se do segundo caso relatado de carcinoma pulmonar de células escamosas que apresenta metástases nas leptomeninges da espinal medula.

Rev Port Pneumol 2008; XIV (6): 875-879

Palavras-chave: Espinal medula, leptomeninges, metástases, ressonância magnética nuclear.
Introduction
Leptomeningeal metastases are being recognized with increasing frequency in last decades as the result of improved therapy of systemic malignancies. Increased life span of cancer patients allow the late expression of leptomeningeal metastases. Advances in technology increase the sensitivity of neuroradiological imaging enables to diagnose the leptomeningeal metastases\(^1\)\(^\text{4}\). Another reason is that the meninges are a sanctuary for many cytotoxic agents that have difficulty crossing the intact blood-CSF barrier, therefore tumor cells in the subarachnoid tumor are not adequately treated and may proliferate\(^5\). Finally infiltration of the leptomeninges by any malignancy is a serious complication that results in substantial morbidity and mortality\(^6\).

In the present report we describe a patient with squamous cell lung cancer, who developed a leptomeningeal infiltration in cauda equina fibers and spinal cord.

Case report
A 58 years-old male patient was evaluated for his treatment management with the diagnosis of low-differentiated squamous cell lung cancer in our clinic in February 2007. He had a mass in the right lung with mediastinal invasion and multiple mediastinal lymphadenopathies in the right inferior paratracheal region. But no other metastases had been detected on abdominal computed tomography (CT), cranial magnetic resonance imaging (MRI), whole body positron emission tomography and skeletal surveys. With the diagnosis of a locally advanced NSCLC he had an induction chemotherapy with cisplatin (75mg/m\(^2\)) and docetaxel (75mg/m\(^2\)). After three cycles of combination chemotherapy, a total dose of 64Gy in 32 fractions external adjuvant radiotherapy to the right lung and mediastinum was performed combined with two cycles of cisplatin (60mg/m\(^2\)). Following chemoradiotherapy, thorax CT revealed, minimal regression in the mass and mediastinal lymph nodes. Five months later he presented with vertigo complaints, cranial MRI revealed multiple metastatic nodules with mass effect in the right superior temporal gyrus, left frontoparietal, frontal and parietal lobes. There was not leptomeningeal enhancement. 30 Gy in 10 fractions palliative whole-brain RT was performed for his brain metastases. After one month, he had low back pain referring to both legs, and weakness in his legs complaints. A spinal MRI was performed to exclude bone metastasis. Innumerable small hypointense nodules were detected along the cauda equina fibers on T2 weighted sagittal scan (Fig. 1A). After the administration of gadolinium chelate, diffuse innumerable nodular enhancement and thickening in the nerve fibers was seen. Small subpial metastatic nodules were also detected in the lower medulla spinalis (Figs. 1B and 2). 17,5 Gy in 5 fractions external palliative radiotherapy was performed to T2-T12 and L1-S2 spinal areas using a posterior field. Unfortunately he died in January 2008.

Discussion
Primary CNS malignancies especially medulloblastoma and CNS lymphoma are the most common cause of leptomeningeal metastases. Cancers such as leukemia, lymphoma, breast cancer, lung cancer, and mela-
The tumor cells could reach the leptomeninges by several mechanisms: Arterial route (in patients with disseminated cancer, the leptomeninges are infiltrated through arachnoid vessels or choroid plexus); direct extension of the leptomeninges or seeding (primary CNS tumors), growing around and along peripheral nerves to the subarachnoid space (systemic tumors), iatrogenic (seeding of subarachnoid space during surgical extirpation of intraparenchymal metastases), entry to the subarachnoid space through the venous plexus of Batson and perivenous spread from adjacent bone marrow metastases. In most cases of breast or lung cancer pure leptomeningeal carcinomatosis is the result of cancer propagation from vertebral or paravertebral metastases. New metastatic deposits along meningeal surfaces which invade subpial parenchyma, penetrate spinal nerve roots, and produce masses in the subarachnoid space.
The most frequently affected regions of the CNS are the basilar cisterns, the posterior fossa, and the cauda equina where slow CSF flow and gravity promote the deposition of circulating cells. Most patients with leptomeningeal metastases have widely disseminated cancer. As systemic therapy improves, progression of disease within the central nervous system becomes an increasing problem. 33-75% of patients with neoplastic meningitis had synchronous intraparenchymal brain metastases. The clinical presentation of leptomeningeal metastases usually involves spinal cord symptoms that attributed to radiculopathy at the involved level, lumbosacral region which is particularly common. Paralysis and vesicorectal disturbance may result from intracranial lesions, and thus it is often difficult to distinguish between the conditions of spinal origin and those of intracranial origin. However, clinical signs and symptoms of leptomeningeal metastases may be absent or may underestimate the extent of macroscopic disease.

Gadolinium-enhanced MRI is the standard and most sensitive radiological technique when leptomeningeal metastasis is suspected. The entire imaging of the neuraxis is mandatory because up to 50% of patients have multi-level disease, which has a poorer prognosis than single site involvement. The imaging features of spinal leptomeningeal metastasis on MRI are: Intradural enhancing nodules in spinal canal, spinal linear enhancement, Spinal cord enlargement and the asymmetry of the roots. High-signal metastatic lesions on T2 imaging may contrast poorly with similarly intense marrow fat, and this sequence should not be exclusively relied on for lesion detection. Diagnostic imaging together with CSF cytology provides useful information, but repeated examinations may be necessary to establish the diagnosis. A raised cell count, increased protein levels, increased levels of lactate dehydrogenase in the CSF when compared with serum levels are all suggestive of leptomeningeal disease, even when cytology is negative. It is important to perform MRI before CSF examination to avoid lumbar puncture-induced gadolinium enhancement of the arachnoid, which may last for weeks to months. This enhancement can easily be mistaken for leptomeningeal disease.

The treatment of leptomeningeal metastasis is palliative because eradication of tumor from the subarachnoid space with existing therapy is extremely rare. The metastasis of systemic cancers usually occurs in the terminal phase of illness. The median survival among patients with leptomeningeal metastasis located in the spinal cord was 2.4 months. The goals of treatment in patients with leptomeningeal metastases are to relieve symptoms, improve or stabilize the neurologic status of the patient, and prolong survival. Despite these measures the prognosis is poor, with a median survival of 2-3 months, and focal neurologic dysfunctions do not improve in most cases. Treatment is usually with external beam radiotherapy, systemic chemotherapy, and intrathecal chemotherapy with methotrexate, thiopeta, and cytarabine. Although surgery is indicated in neurological deficit, spinal instability and radiation treatment failure.
As a conclusion, spinal leptomeningeal metastasis is extremely rarely seen in squamous-cell lung cancer. Contrast-enhanced MR imaging is useful in the diagnosis of pial spread of metastatic disease in patients with a known primary malignancy and unexplained neurologic signs or symptoms.

References